V8.0 版权所有© 2001-2026 渝B2-20050021-1
渝公网安备 50019002500403号违法和不良信息举报中心举报邮箱：jubao@cqvip.com
互联网出版许可证 新出网证(渝)字10号机构客服热线 023-67882612
- Expert Consensus on the Interventional Treatment of Choledocholithiasis with Integrative Medicine 认领 引用 被引量：5
- 1
- 作者 Bin Liu Zhongmin Wang +15 位作者 Jinhe Guo Honglei Wu Kai Zhang Tao Yu Zhengguang Du Wenxia Zhao Long Jin Chongzhong Liu Zan Fu Jiangguang Sun Kun Gao Haibo Shao Duiping Feng Dongfeng Shen Hongling Jia Yuliang Li 《Chinese Medicine and Natural Products》 CAS 2023年第1期1-8,I0002,I0003,共8页
- Percutaneous transhepatic papillary ballon drainage(PTPBD)is a newly emerging interventional treatment modality for choledocholithiasis in China.Compared with other treatments,it has some advantages.Traditional Chines... Percutaneous transhepatic papillary ballon drainage(PTPBD)is a newly emerging interventional treatment modality for choledocholithiasis in China.Compared with other treatments,it has some advantages.Traditional Chinese medicine has been proven to have certain advantages in the treatment of choledocholithiasis,with reliable efficacy,few side effects,and a low recurrence rate.To standardize the clinical practice of choledocholithiasis,facilitate the application of PTPBD,and improve the diagnosis and treatment of integrative medicine,the Chinese College of Interventionalists organized multidisciplinary experts to discuss and formulate this consensus.This consensus aims to regulate the patient selection and technical process of PTPBD and the diagnosis and treatment scheme of integrative medicine. 展开更多
- 关键词 choledocholithiasis integrative medicine expert consensus interventional treatment
- One-year status of hepatic venous pressure gradient measurement from 85 hospitals in China 认领 引用
- 2
- 作者 Jitao Wang Ting Cui +87 位作者 Linpeng Zhang Zhiping Yan Lei Li Jinjun Chen Junhui Sun Hua Xiang He Zhu Hao Wu Jiancuo Gengzang Feng Zhang Wei Wu Guohong Cao Wuhua Guo Haibin Shi Hui Xue Guangjun Huang Qiang Yu Meng Niu Huiling Xiang Derun Kong Wei Gou Xuefeng Luo Fuliang He Min Yuan Wei Liu Yong Wang Hongjie Hu Xiaoli Zhu Tao Yu Qinxue Sun Wei Qu Ting Lu Deqiang Ma Li Zhang Jun Ma Jun Yang Ketao Mu Xiaoliang Zhu Kai Xiong Huiguo Ding Shengjuan Yao Mingsheng Huang Fang Wang Zexin Wang Yong Huang Jianan Li Hongfeng Yi Birun Huang Zhongwei Zhao Duiping Feng Yanming Lei Changlong Hou Wenbo Guo Shirong Liu Gaojun Teng Kangshun Zhu Fan Wu Xiaogang Hu Wenfeng Zhang Shaoqi Yang Zhouchao Hu Pengfei Pang Shaowu Zhuang Weidong Wang Qingliang Zhu Kunpeng Zhang Chengyu Liu Dongliang Li Chao Ma Hong Jiang Xingong Zhao Weixin Ren Zhiwei Wang Lei Yu Fuhuang Lin Chaoguang Yan Feng Wang Lei Yu Hui Huan Wenyong Shen Shaofei He Chengda Zhang Jinlun Bao Jiangtao Liu Jun Wu Jianbo Zhao Jian Zhang Xiaolong Qi 《Portal Hypertension & Cirrhosis》 2024年第2期116-123,共8页
- Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in China.This article aimed to in... Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in China.This article aimed to investigate the status of hepatic venous pressure gradient measurement in China in 2022.Methods:We investigated the overall status of HVPG technology in China-including hospital distribution,hospital level,annual number of cases,catheters used,average cost,indications,and current challenges by using online questionnaire.By counting the number and percentages of cases of these results,we hope to clarify the current status of HVPG measurements in China.Results:According to the survey,85 hospitals in China used HVPG technology in 2022 distributed across 29 provinces.A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022,of which 2813 cases(56.4%)were measured alone.The average cost of HVPG measurement was 5646.8±2327.9 CNY.Of the clinical teams who performed the measurements(sometimes multiple per hospital),94.3%(82/87)used the balloon method,and the majority of the teams(72.4%,63/87)used embolectomy catheters.Conclusions:This survey clarified the clinical application status of HVPG in China and confirmed that some medical institutions in China have established a foundation for this technology.It is still necessary to continue promoting and popularizing this technology in the future. 展开更多
- 关键词 application status hepatic vein pressure gradient questionnaire survey
-
- Psoas muscle index in sarcopenia following transjugular intrahepatic portosystemic shunt:A multicenter,retrospective study 认领 引用 被引量：2
- 3
- 作者 Tongqiang Li Ze Wang +10 位作者 Yang Liu Liguo Dai Xiaoli Zhu Jiacheng Liu Qikun Guo Weijie Luo Yaowei Bai Wei Luo Menglan Chu Duiping Feng Bin Xiong 《Portal Hypertension & Cirrhosis》 2024年第4期173-183,共11页
- Aims:Although the skeletal muscle index at the third lumbar vertebra(L3-SMI)is commonly utilized for the diagnosis of sarcopenia,the psoas muscle index at L3(L3-PMI)may serve as a reliable alternative indicator.This s... Aims:Although the skeletal muscle index at the third lumbar vertebra(L3-SMI)is commonly utilized for the diagnosis of sarcopenia,the psoas muscle index at L3(L3-PMI)may serve as a reliable alternative indicator.This study aims to investigate the application of the PMI in patients who have undergone transjugular intrahepatic portosystemic shunt(TIPS).Methods:This study included a cohort of 406 patients with cirrhosis who underwent TIPS between February 2016 and July 2022 across three medical centers in China.Clinical and imaging data,specifically L3-SMI and L3-PMI,were collected for these patients.The prognosis of the patients was assessed through re-examinations and telephone follow-ups,which extended up to 5 years.The diagnostic thresholds for sarcopenia,as defined by L3-PMI and L3-SMI,were established at 6.36 or 42.00 cm2/m2 for males and 3.92 or 38.00 cm2/m2 for females,respectively.Cox proportional hazards and Kaplan–Meier(K-M)analyses were employed to evaluate patient survival.Results:The findings indicated that both L3-PMI and L3-SMI before TIPS were independent risk factors for mortality.The results of the paired t-test demonstrated a significant increase in L3-PMI 1 month post-TIPS(5.11±1.81 vs.5.71±1.90 cm2/m2 ,p<0.001),whereas L3-SMI did not exhibit a significant increase until 6 months post-TIPS(45.45±9.41 vs.48.59±10.38 cm2/m2 ,p<0.001).Among these patients,191(47.0%)and 159(39.2%)were diagnosed with sarcopenia according to the L3-PMI and L3-SMI models,respectively.Patients identified as sarcopenic by both indicators demonstrated a significantly lower survival rate(L3-SMI model:hazard ratio[HR],1.913;95%confidence interval[CI],1.094–3.410;log-rank p=0.020;L3-PMI model:HR,1.867;95%CI,1.059–3.290;log-rank p=0.030).In sarcopenic patients,the reversal of sarcopenia associated with improved survival occurred 1 month after TIPS in the L3-PMI model(HR,2.675;95%CI,1.245–5.735;log-rank p=0.012),while a similar effect was not observed until 6 months post-TIPS in the L3-SMI model(HR,3.342;95%CI,1.477–7.560;logrank p=0.004).Conclusions:L3-PMI and L3-SMI demonstrate comparable efficacy in diagnosing cirrhosis-related sarcopenia.Furthermore,L3-PMI has the capacity to identify improvements in sarcopenia as early as 1 month following TIPS,thereby providing earlier insights into patient survival outcomes. 展开更多
- 关键词 cirrhosis portal hypertension psoas muscle index sarcopenia skeletal muscle index transjugular intrahepatic portosystemic shunt
-
- 题名Expert Consensus on the Interventional Treatment of Choledocholithiasis with Integrative Medicine 认领 引用 被引量：5
- 1
- 作者 Bin Liu Zhongmin Wang Jinhe Guo Honglei Wu Kai Zhang Tao Yu Zhengguang Du Wenxia Zhao Long Jin Chongzhong Liu Zan Fu Jiangguang Sun Kun Gao Haibo Shao Duiping Feng Dongfeng Shen Hongling Jia Yuliang Li
- 机构 Department of Interventional Medicine,The Second Hospital of Shandong University Department of Interventional Radiology,School of Medicine,Shanghai Jiao Tong University,Ruijin Hospital Department of Interventional and Vascular Surgery,Zhongda Hospital Affiliated to Southeast University Department of Gastroenterology,The Second Hospital of Shandong University Department of Hepatobiliary Surgery,The Third Hospital of Shandong Province Department of Gastroenterology,Qilu Hospital of Shandong University Department of Gastroenterology,Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University Department of Spleen,Stomach and Hepatobiliary Diseases,The First Hospital Affiliated to Henan University of Chinese Medicine Department of Interventional Radiology,Beijing Friendship Hospital Affiliated to Capital Medical University Department of Hepatobiliary Surgery,The Second Hospital of Shandong University Department of General Surgery,Jiangsu Provincial People's Hospital Department of Hepatobiliary Medicine,Affiliated Hospital of Shandong University of Traditional Chinese Medicine Department of Interventional Medicine,Beijing Chaoyang Hospital Department of Interventional Therapy,The First Affiliated Hospital of China Medical University,Shenyang Department of Interventional Radiology,The First Hospital of Shanxi Medical University,Taiyuan Department of Interventional Vascular Surgery,Shanxi Provincial Hospital,Taiyuan Department of Acupuncture and Moxibustion,The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine
- 出处 《Chinese Medicine and Natural Products》 CAS 2023年第1期1-8,I0002,I0003,共8页
- 基金 by the Program for Integrated Traditional Chinese and Western Medicine in Shandong Province of China(YXH2019ZXY007) Ji’nan Professionals Development Special Fund(20228118) +1 种基金 Science and Technology Project of(Sinopec Group)Shengli Petroleum Administration Co.,Ltd(GKY2001) Science and Technology Project of Ji'nan Health Committee(2020-3-65).
- 摘要 Percutaneous transhepatic papillary ballon drainage(PTPBD)is a newly emerging interventional treatment modality for choledocholithiasis in China.Compared with other treatments,it has some advantages.Traditional Chinese medicine has been proven to have certain advantages in the treatment of choledocholithiasis,with reliable efficacy,few side effects,and a low recurrence rate.To standardize the clinical practice of choledocholithiasis,facilitate the application of PTPBD,and improve the diagnosis and treatment of integrative medicine,the Chinese College of Interventionalists organized multidisciplinary experts to discuss and formulate this consensus.This consensus aims to regulate the patient selection and technical process of PTPBD and the diagnosis and treatment scheme of integrative medicine.
- 关键词 choledocholithiasis integrative medicine expert consensus interventional treatment
- Keywords 胆总管结石 中西医结合 专家共识 介入治疗
- 分类号 R575.7 [医药卫生—消化系统]
- 题名One-year status of hepatic venous pressure gradient measurement from 85 hospitals in China 认领 引用
- 2
- 作者 Jitao Wang Ting Cui Linpeng Zhang Zhiping Yan Lei Li Jinjun Chen Junhui Sun Hua Xiang He Zhu Hao Wu Jiancuo Gengzang Feng Zhang Wei Wu Guohong Cao Wuhua Guo Haibin Shi Hui Xue Guangjun Huang Qiang Yu Meng Niu Huiling Xiang Derun Kong Wei Gou Xuefeng Luo Fuliang He Min Yuan Wei Liu Yong Wang Hongjie Hu Xiaoli Zhu Tao Yu Qinxue Sun Wei Qu Ting Lu Deqiang Ma Li Zhang Jun Ma Jun Yang Ketao Mu Xiaoliang Zhu Kai Xiong Huiguo Ding Shengjuan Yao Mingsheng Huang Fang Wang Zexin Wang Yong Huang Jianan Li Hongfeng Yi Birun Huang Zhongwei Zhao Duiping Feng Yanming Lei Changlong Hou Wenbo Guo Shirong Liu Gaojun Teng Kangshun Zhu Fan Wu Xiaogang Hu Wenfeng Zhang Shaoqi Yang Zhouchao Hu Pengfei Pang Shaowu Zhuang Weidong Wang Qingliang Zhu Kunpeng Zhang Chengyu Liu Dongliang Li Chao Ma Hong Jiang Xingong Zhao Weixin Ren Zhiwei Wang Lei Yu Fuhuang Lin Chaoguang Yan Feng Wang Lei Yu Hui Huan Wenyong Shen Shaofei He Chengda Zhang Jinlun Bao Jiangtao Liu Jun Wu Jianbo Zhao Jian Zhang Xiaolong Qi
- 机构 Hebei Provincial Key Laboratory of Cirrhosis&Portal Hypertension,Xingtai People's Hospital,Xingtai Center of Portal Hypertension,Department of Radiology,Zhongda Hospital,School of Medicine,Southeast University Department of Interventional Therapy,Beijing Shijitan Hospital Affiliated to Capital Medical University Department of Intervention,Taiyuan Third People's Hospital,Taiyuan Department of Intervention,Zhongshan Hospital Affiliated to Fudan University Department of Interventional Medicine,The First Hospital of Lanzhou University,Lanzhou Department of Infectious Diseases,Nanfang Hospital of Southern Medical University Hepatobiliary and Pancreatic Intervention Center,The First Affiliated Hospital of Zhejiang University School of Medicine Interventional Vascular Surgery,Hunan Provincial People's Hospital Department of Intervention,Sixth People's Hospital of Shenyang,Shenyang Department of Gastroenterology,West China Hospital of Sichuan University Department of Intervention,The Fourth People's Hospital of Qinghai Province Department of Gastroenterology,Nanjing Drum Tower Hospital Department of Gastroenterology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou Department of Radiology,Shulan（Hangzhou）Hospital Department of Intervention,Mengchao Hepatobiliary Hospital of Fujian Medical University Department of Interventional Radiology,The First Affiliated Hospital of Nanjing Medical University Department of Gastroenterology,The First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Department of Gastroenterology,Shandong Provincial Hospital Affiliated to Shandong First Medical University Department of Interventional Radiology,Fifth Medical Center of General Hospital of Chinese People's Liberation Army Department of Interventional Therapy,The First Affiliated Hospital of China Medical University,Shenyang Department of Gastroenterology,Tianjin Third Central Hospital Department of Gastroenterology,The First Affiliated Hospital of Anhui Medical University Department of Metabolic Hepatology,Qingdao Sixth People's Hospital,Qingdao Liver Disease Center,Beijing Friendship Hospital,Capital Medical University Department of Intervention,Shanghai Public Health Clinical Center Department of Intervention,People's Hospital of Lishui,Zhejiang Province Department of Interventional Radiology and Vascular Surgery,The Second Affiliated Hospital of Hainan Medical University Department of Radiology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine Department of Intervention,The First Affiliated Hospital of Soochow University Longwan Interventional and Vascular Surgery,Huludao Central Hospital,Huludao Department of Intervention,Ningbo Medical Center Lihuili Hospital Department of Gastroenterology,People's Hospital of Rizhao Department of Gastroenterology,Yangquan Third People's Hospital,Yangquan Department of Infectious Diseases,Taihe Hospital,Shiyan City,Hubei Province Department of Interventional Therapy,Guilin People's Hospital,Guangxi Interventional Vascular Surgery,People's Hospital of Ningxia Hui Autonomous Region,Yinchuan,Ningxia Department of Interventional Therapy,Yantai Yuhuangding Hospital Affiliated to Qingdao University Department of Radiology,Tongji Hospital Department of General Surgery,Donggang Campus,The First Hospital of Lanzhou University,Lanzhou Department of Gastroenterology,The Second Affiliated Hospital of Nanchang University,Nanchang Liver Disease Digestion Center,Beijing You'an Hospital,Capital Medical University Department of Radiology,Tianjin Second People's Hospital Department of Intervention,The Third Affiliated Hospital,Sun Yat‐sen University Second Department of Hepatology,Shenzhen Third People's Hospital Department of Interventional Radiology,The Affiliated Hospital of Inner Mongolia Medical University,Inner Mongolia Department of Intervention,Zigong Fourth People's Hospital Department of Hepatology,Jiamusi Infectious Disease Hospital,Jiamusi Department of Gastroenterology,Wuhan NO.1 Hospital Interventional Vascular Surgery,Jingzhou First People's Hospital,Jingzhou Interventional Diagnosis and Treatment Center,Lishui Central Hospital Department of Oncological and Vascular Intervention,First Hospital of Shanxi Medical University,Taiyuan Department of Interventional Radiology,People's Hospital of Tibet Autonomous Region Department of Intervention Tumor,The First Affiliated Hospital of University of Science and Technology of China Department of Interventional Radiology,The First Affiliated Hospital,Sun Yatsen University Department of Infectious Diseases,Qufu People's Hospital Interventional and Vascular Surgery,Zhongda Hospital Southeast University Department of Minimally Invasive Intervention,The Second Affiliated Hospital of Guangdong Medical University Department of Gastroenterology,The Central Hospital of Wuhan,Tongji Medical College,Huazhong University of Science and Technology Tumor and Vascular Intervention Department,Jinhua Medical Central Hospital Department of Infectious Diseases,The First Affiliated Hospital of Nanchang University,Nanchang Department of Gastroenterology,General Hospital of Ningxia Medical University,Yinchuan,Ningxia Interventional Diagnosis and Treatment Center,Zhoushan Hospital of Zhejiang Province,Zhoushan Department of Interventional Vascular Surgery,The Fifth Affiliated Hospital of Sun Yat‐sen University Department of Interventional Medicine,Zhangzhou Hospital Affiliated to Fujian Medical University,Zhangzhou Department of Hepatobiliary,Pancreatic,and Splenic Surgery,Shunde Hospital of Southern Medical University Department of Gastroenterology,The Affiliated Hospital of Southwest Medical University Department of Hepatobiliary Medicine,The 900th Hospital of the Joint Logistics Support Force Department of Gastroenterology,The Second People's Hospital of Fuyang City,Anhui Province Department of Infectious Diseases,The NO.2 Affiliated Hospital of Air Force Medical University,Shaanxi Department of Gastroenterology,Weinan Central Hospital,Shaanxi Interventional Treatment Center,The First Affiliated Hospital of Xinjiang Medical University,Xinjiang Endovascular Surgery,The First Affiliated Hospital of Zhengzhou University Department of Interventional Therapy,The People's Hospital of Guangxi Zhuang Autonomous Region,Nanning,Guangxi Comprehensive Intervention Department,Hainan General Hospital Department of Gastroenterology,Kuitun Hospital,Xinjiang Department of Interventional Therapy,The First Affiliated Hospital of Dalian Medical University Department of Intervention,Sanming First Hospital Affiliated to Fujian Medical University,Sanming Department of Gastroenterology,Hospital of the People's Government of Tibet Autonomous Region in Chengdu Office Department of Gastroenterology,Fuling Hospital Affiliated to Chongqing University Department of Radiology,Mengzi People's Hospital Department of Gastroenterology,The Third People's Hospital of Mianyang,Mianyang Department of Gastroenterology,Shannan People's Hospital,Shannan Department of Gastroenterology,Hainan Hospital of Chinese PLA General Hospital Department of Intervention,The Second People's Hospital of Lanzhou City,Lanzhou Department of Vascular and Intervention,Nanfang Hospital of Southern Medical University Department of Interventional Radiology,The Affiliated Hospital of Jiangsu University,Zhenjiang
- 出处 《Portal Hypertension & Cirrhosis》 2024年第2期116-123,共8页
- 摘要 Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in China.This article aimed to investigate the status of hepatic venous pressure gradient measurement in China in 2022.Methods:We investigated the overall status of HVPG technology in China-including hospital distribution,hospital level,annual number of cases,catheters used,average cost,indications,and current challenges by using online questionnaire.By counting the number and percentages of cases of these results,we hope to clarify the current status of HVPG measurements in China.Results:According to the survey,85 hospitals in China used HVPG technology in 2022 distributed across 29 provinces.A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022,of which 2813 cases(56.4%)were measured alone.The average cost of HVPG measurement was 5646.8±2327.9 CNY.Of the clinical teams who performed the measurements(sometimes multiple per hospital),94.3%(82/87)used the balloon method,and the majority of the teams(72.4%,63/87)used embolectomy catheters.Conclusions:This survey clarified the clinical application status of HVPG in China and confirmed that some medical institutions in China have established a foundation for this technology.It is still necessary to continue promoting and popularizing this technology in the future.
- 关键词 application status hepatic vein pressure gradient questionnaire survey
- 分类号 R575.2 [医药卫生—消化系统]
-
- 题名Psoas muscle index in sarcopenia following transjugular intrahepatic portosystemic shunt:A multicenter,retrospective study 认领 引用 被引量：2
- 3
- 作者 Tongqiang Li Ze Wang Yang Liu Liguo Dai Xiaoli Zhu Jiacheng Liu Qikun Guo Weijie Luo Yaowei Bai Wei Luo Menglan Chu Duiping Feng Bin Xiong
- 机构 Department of Interventional Radiology,The First Affiliated Hospital of Guangzhou Medical University Department of Radiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology Department of Interventional Radiology,The First Affiliated Hospital of Soochow University Department of Oncological and Vascular Intervention,First Hospital of Shanxi Medical University,Taiyuan Shanxi Radiation and Therapy（Interventional Radiology）Clinical Medicine Research Center,First Hospital of Shanxi Medical University,Taiyuan Hepatobiliary and Pancreatic Interventional Treatment Center,Division of Hepatobiliary and Pancreatic Surgery,The First Affiliated Hospital,Zhejiang University School of Medicine Zhejiang Provincial Key Laboratory of Pancreatic Disease,The First Affiliated Hospital,Zhejiang University School of Medicine
- 出处 《Portal Hypertension & Cirrhosis》 2024年第4期173-183,共11页
- 基金 the approval of Ethics Committees of Union Hospital Tongji Medical College,Huazhong University of Science and Technology(No.2022-S207) The First Affiliated Hospital of Soochow University(No.2022412) The First Hospital of Shanxi Medical University(No.2022KK094).
- 摘要 Aims:Although the skeletal muscle index at the third lumbar vertebra(L3-SMI)is commonly utilized for the diagnosis of sarcopenia,the psoas muscle index at L3(L3-PMI)may serve as a reliable alternative indicator.This study aims to investigate the application of the PMI in patients who have undergone transjugular intrahepatic portosystemic shunt(TIPS).Methods:This study included a cohort of 406 patients with cirrhosis who underwent TIPS between February 2016 and July 2022 across three medical centers in China.Clinical and imaging data,specifically L3-SMI and L3-PMI,were collected for these patients.The prognosis of the patients was assessed through re-examinations and telephone follow-ups,which extended up to 5 years.The diagnostic thresholds for sarcopenia,as defined by L3-PMI and L3-SMI,were established at 6.36 or 42.00 cm2/m2 for males and 3.92 or 38.00 cm2/m2 for females,respectively.Cox proportional hazards and Kaplan–Meier(K-M)analyses were employed to evaluate patient survival.Results:The findings indicated that both L3-PMI and L3-SMI before TIPS were independent risk factors for mortality.The results of the paired t-test demonstrated a significant increase in L3-PMI 1 month post-TIPS(5.11±1.81 vs.5.71±1.90 cm2/m2 ,p<0.001),whereas L3-SMI did not exhibit a significant increase until 6 months post-TIPS(45.45±9.41 vs.48.59±10.38 cm2/m2 ,p<0.001).Among these patients,191(47.0%)and 159(39.2%)were diagnosed with sarcopenia according to the L3-PMI and L3-SMI models,respectively.Patients identified as sarcopenic by both indicators demonstrated a significantly lower survival rate(L3-SMI model:hazard ratio[HR],1.913;95%confidence interval[CI],1.094–3.410;log-rank p=0.020;L3-PMI model:HR,1.867;95%CI,1.059–3.290;log-rank p=0.030).In sarcopenic patients,the reversal of sarcopenia associated with improved survival occurred 1 month after TIPS in the L3-PMI model(HR,2.675;95%CI,1.245–5.735;log-rank p=0.012),while a similar effect was not observed until 6 months post-TIPS in the L3-SMI model(HR,3.342;95%CI,1.477–7.560;logrank p=0.004).Conclusions:L3-PMI and L3-SMI demonstrate comparable efficacy in diagnosing cirrhosis-related sarcopenia.Furthermore,L3-PMI has the capacity to identify improvements in sarcopenia as early as 1 month following TIPS,thereby providing earlier insights into patient survival outcomes.
- 关键词 cirrhosis portal hypertension psoas muscle index sarcopenia skeletal muscle index transjugular intrahepatic portosystemic shunt
- 分类号 R685 [医药卫生—骨科学] R575.2 [医药卫生—外科学]
-
